STAAR Surgical Files Definitive Additional Materials

TL;DR

STAAR Surgical dropped more proxy docs, check 'em out.

AI Summary

STAAR Surgical Company filed a DEFA14A on October 6, 2025, which includes a press release addressing "Broadw". The filing is a definitive additional material, indicating it's supplementary information to a proxy statement. No fee was required for this filing.

Why It Matters

This filing provides additional information to shareholders regarding company matters, potentially impacting investment decisions and corporate governance.

Risk Assessment

Risk Level: low — This filing is a routine SEC disclosure (DEFA14A) and does not appear to contain immediate, high-impact financial or operational news.

Key Players & Entities

• STAAR Surgical Company (company) — Registrant
• 0001193125-25-230935.txt (document) — Accession Number
• October 6, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $28 — con's compelling, premium cash value of $28 per share. 4. Broadwood allegation:
• $16.8 million — ed 55% and STAAR reported a net loss of $16.8 million in the second quarter of 2025. Net sal
• $340 million — f STAAR achieves its 2026 projection of $340 million in net sales, that will only yield a th
• $322 million — yield a three-year CAGR of 2% from the $322 million in net sales it reported in 2023. 2.
• $261.7 million — 2024 offer: STAAR's LTM net sales were $261.7 million in the second quarter of 2022 and grew
• $332.9 million — the second quarter of 2022 and grew to $332.9 million in the second quarter of 2024, which re
• $305.9 million — ober 2024. STAAR's LTM net sales were $305.9 million in the second quarter of 2023 and contr
• $224.4 million — econd quarter of 2023 and contracted to $224.4 million in the second quarter of 2025, which re
• $15.09 — stock price was well established in the $15.09 to $20.27 range in the five months prio
• $20.27 — e was well established in the $15.09 to $20.27 range in the five months prior to the t
• $19.00 — edian sell-side analyst price target of $19.00 per share as of just prior to the trans

Filing Documents

• d70630ddefa14a.htm (DEFA14A) — 67KB
• g70630g1006081731802.jpg (GRAPHIC) — 3KB
• 0001193125-25-230935.txt ( ) — 73KB

Forward-Looking Statements

Forward-Looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not statements of historical fact are forward-looking statements. These forward-looking statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR's stock pr

Forward-looking statements speak only as of the date they are made and, except as may be required under

Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, STAAR undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. STAAR Contacts: Niko Liu, CFA United States: +1 626-303-7902 (ext 3023) Hong Kong: +852-6092-5076 nliu@staar.com investorrelations@staar.com Connie Johnson +1 626-303-7902 (ext 2207) cjohnson@staar.com Lucas Pers / Alexandra Benedict Joele Frank, Wilkinson Brimmer Katcher +1 212-895-8692 / +1 212-895-8644

View Full Filing

View this DEFA14A filing on SEC EDGAR